Summary & Overview
HCPCS S3846: Genetic Testing for Hemoglobin E Beta-Thalassemia
HCPCS Level II code S3846 denotes genetic testing for hemoglobin E beta-thalassemia, a targeted molecular diagnostic assay used to identify pathogenic variants in individuals with suspected hemoglobin E and beta-thalassemia compound conditions. This code represents specialized laboratory services that have clinical importance for diagnosis, carrier detection, and care planning for hereditary hemoglobinopathies. Nationally, such testing supports newborn screening follow-up, reproductive risk assessment, and management of patients with microcytic anemia not explained by iron deficiency.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage and payment benchmarks, common billing considerations, and the clinical context in which S3846 is used. The publication provides national-level benchmarks where available, summarizes relevant policy updates affecting laboratory genetic testing reimbursement, and outlines clinical scenarios driving utilization. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code S3846 describes genetic testing for hemoglobin E beta-thalassemia, a molecular diagnostic service used to identify genetic variants associated with hemoglobin E and beta-thalassemia compound states. This testing supports diagnostic confirmation, carrier screening, and clinical decision-making related to inherited hemoglobinopathies.
-
Service type: Genetic testing / molecular diagnostic testing
-
Typical site of service: Clinical laboratory or outpatient diagnostic laboratory setting
Clinical & Coding Specifications
Clinical Context
A 28-year-old pregnant woman of Southeast Asian descent presents to a maternal-fetal medicine clinic after routine hemoglobin electrophoresis showed microcytic anemia and an abnormal hemoglobin fraction suggestive of Hemoglobin E trait. Her partner is known to be a carrier of beta-thalassemia. The obstetrician orders targeted genetic testing for hemoglobin E beta-thalassemia to clarify fetal risk, guide prenatal counseling, and inform pregnancy management. Blood is drawn in the outpatient lab; samples are sent to a reference molecular diagnostics laboratory. Results are reported to the ordering clinician and documented in the prenatal record; genetic counseling is provided to the patient and partner.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the laboratory documents substantially greater effort or complexity beyond typical testing (rare for single molecular test). |
26 | Professional component | Use when billing only the professional interpretation component separate from technical laboratory services. |